公开(公告)号：WO2022226311A1

公开(公告)日：2022-10-27

申请号：PCT/US2022/025955

申请日：2022-04-22

Applicant: ABBOTT LABORATORIES

Inventor： BUCK, Rachael ,  DAS, Tapas ,  HILL, David ,  VURMA, Mustafa

IPC: A23L33/00 ,  A61P11/00

Abstract: Disclosed are methods of and nutritional compositions for treating or improving at least one marker of lung health in an individual. The nutritional compositions include a combination of a human milk oligosaccharide component and a designed lipid component.

公开(公告)号：WO2010127198A1

公开(公告)日：2010-11-04

申请号：PCT/US2010/033085

申请日：2010-04-30

Applicant: ABBOTT LABORATORIES ,  ABBOTT GMBH & CO. KG ,  CATRON, Nathaniel ,  FICKES, Michael ,  FISCHER, Cristina ,  GOKHALE, Rajeev ,  HAIGHT, Anthony R. ,  HEEMSTRA, Katherine ,  HILL, David ,  KNOBLOCH, Martin, Dr. ,  KOSTELAC, Drazen, Dr. ,  LAFOUNTAINE, Justin S. ,  LI, Yanxia ,  LIEPOLD, Bernd, Dr. ,  MARSH, Kennan ,  MILLER, Jonathan Mark ,  PACKHAEUSER, Claudia, Dr. ,  SANZGIRI, Yeshwant ,  SCHMITT, Eric ,  SHI, Yi ,  STEIGER, Norbert ,  TONG, Ping ,  WU, Huailiang ,  ZHANG, Geoff ,  ZHOU, Deliang

Inventor： CATRON, Nathaniel ,  FICKES, Michael ,  FISCHER, Cristina ,  GOKHALE, Rajeev ,  HAIGHT, Anthony R. ,  HEEMSTRA, Katherine ,  HILL, David ,  KNOBLOCH, Martin, Dr. ,  KOSTELAC, Drazen, Dr. ,  LAFOUNTAINE, Justin S. ,  LI, Yanxia ,  LIEPOLD, Bernd, Dr. ,  MARSH, Kennan ,  MILLER, Jonathan Mark ,  PACKHAEUSER, Claudia, Dr. ,  SANZGIRI, Yeshwant ,  SCHMITT, Eric ,  SHI, Yi ,  STEIGER, Norbert ,  TONG, Ping ,  WU, Huailiang ,  ZHANG, Geoff ,  ZHOU, Deliang

IPC: A61K9/00 ,  A61K31/5377 ,  A61K47/00 ,  A61K47/02 ,  A61K47/14 ,  A61K47/20

CPC classification number: A61K31/5377 ,  A61K9/08 ,  A61K9/10 ,  A61K9/146 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/4858 ,  A61K9/4866

Abstract: An orally deliverable pharmaceutical composition comprises as a sole or first active ingredient a compound of Formula I defined herein or a pharmaceutically acceptable salt thereof, for example ABT-263 free base or ABT-263 bis -HCl salt, dispersed, in a free base equivalent amount of at least about 2.5% by weight of the composition, in a pharmaceutically acceptable carrier; wherein said active ingredient is in solid-state form and/or the composition further comprises, dispersed in the carrier, a pharmaceutically acceptable heavier-chalcogen antioxidant in an amount effective to inhibit oxidation of the active ingredient at a thioether linkage thereof. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Abstract translation: 可口服递送的药物组合物包含作为唯一或第一活性成分的本文定义的式I化合物或其药学上可接受的盐，例如以游离碱当量分散的ABT-263游离碱或ABT-263双-HCl盐 至少约2.5重量％的组合物，在药学上可接受的载体中; 其中所述活性成分是固态形式和/或所述组合物还包含以有效抑制活性成分在其硫醚键的氧化的量分散在载体中的药学上可接受的较重硫族元素抗氧化剂。 该组合物适合于有需要的受试者的口服给药，用于治疗以一种或多种抗凋亡Bcl-2家族蛋白（例如癌症）过表达为特征的疾病。

公开(公告)号：WO2022266058A1

公开(公告)日：2022-12-22

申请号：PCT/US2022/033376

申请日：2022-06-14

Applicant: ABBOTT LABORATORIES

Inventor： HILL, David ,  BUCK, Rachael

IPC: A23C23/00 ,  A23L33/125 ,  A23L33/135 ,  A23L33/00

Abstract: Provided herein are methods and nutritional compositions for treating gas in an individual. The nutritional compositions are useful for treating gas in an individual and include a mixture of human milk oligosaccharides and a probiotic blend of Bifidobacterium lactis, Bifidobacterium infantis, and Streptococcus thermophilus.

公开(公告)号：WO2010127191A1

公开(公告)日：2010-11-04

申请号：PCT/US2010/033073

申请日：2010-04-30

Applicant: ABBOTT LABORATORIES ,  FISCHER, Cristina ,  GOKHALE, Rajeev ,  HEEMSTRA, Katherine ,  HILL, David ,  MARSH, Kennan ,  SCHMITT, Eric ,  SHI, Yi ,  TONG, Ping ,  ZHOU, Deliang

Inventor： FISCHER, Cristina ,  GOKHALE, Rajeev ,  HEEMSTRA, Katherine ,  HILL, David ,  MARSH, Kennan ,  SCHMITT, Eric ,  SHI, Yi ,  TONG, Ping ,  ZHOU, Deliang

IPC: A61K9/00 ,  A61K31/5377

CPC classification number: A61K9/4866 ,  A61K9/1652 ,  A61K9/2054 ,  A61K31/5377

Abstract: An orally deliverable pharmaceutical composition comprises (a) a pharmaceutically acceptable acid addition salt of ABT-263 in solid particulate form, and (b) a plurality of pharmaceutically acceptable excipients including at least a solid diluent and a solid disintegrant; wherein the salt is formed from more than one equivalent of acid per equivalent of ABT-263. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Abstract translation: 可口服递送的药物组合物包含（a）固体颗粒形式的ABT-263的药学上可接受的酸加成盐，和（b）多种药学上可接受的赋形剂，包括至少一种固体稀释剂和固体崩解剂; 其中所述盐由每当量ABT-263的多于一当量的酸形成。 该组合物适合于有需要的受试者的口服给药，用于治疗以一种或多种抗凋亡Bcl-2家族蛋白（例如癌症）过表达为特征的疾病。